1. Home
  2. STBA vs COAG Comparison

STBA vs COAG Comparison

Compare STBA & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo S&T Bancorp Inc.

STBA

S&T Bancorp Inc.

HOLD

Current Price

$50.88

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

COAG

Hemab Therapeutics Holdings Inc. Common Stock

HOLD

Current Price

$34.49

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STBA
COAG
Founded
1902
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
STBA
COAG
Price
$50.88
$34.49
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$53.33
★ $62.67
AVG Volume (30 Days)
192.1K
★ 349.1K
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 3.03%
N/A
EPS Growth
★ 2.35
N/A
EPS
★ 1.96
N/A
Revenue
N/A
N/A
Revenue This Year
$3.87
N/A
Revenue Next Year
$3.75
N/A
P/E Ratio
$24.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.68
$27.38
52 Week High
$53.50
$55.42

Technical Indicators

Market Signals
Indicator
STBA
COAG
Relative Strength Index (RSI) 62.35 50.62
Support Level $50.43 $28.46
Resistance Level $53.50 $38.87
Average True Range (ATR) 0.97 2.45
MACD 0.22 1.01
Stochastic Oscillator 91.66 79.65

Price Performance

Historical Comparison
STBA
COAG

About STBA S&T Bancorp Inc.

S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: